Abstract
Drug development is a complex undertaking, not an academic exercise. The key players, mainly pharmaceutical industry, regulatory authorities and academia, have different logics and interests. Industry consists of large, medium, and small companies who compete (or cooperate), win or fail. For some decades large companies seemed to set the tone in drug development, but that paradigm may be changing. Pediatric legislation has imposed the logic of public health over this already complex process. The intention is certainly laudable. The key question is if it works, and to what degree the US and EU legislation are comparable. The breakthrough improvements in pediatric oncology in the last decades happened without direct contribution from regulatory authorities. The successful treatment schemes for children with cancer are off-label and will remain so. Breakthrough innovations in rare pediatric diseases such as cystic fibrosis or enzyme deficiencies were not triggered by pediatric legislation. The number of label changes, of submitted pediatric investigation plans (PIPs), or of clinical trials that companies must commit to have in themselves limited significance. Do all label changes improve child treatment? Do trials in rare diseases make sense if there are not enough patients on this planet? Does the interference of the European Medicines Agency (EMA) and its pediatric committee (PDCO) in worldwide research in rare pediatric diseases promote child health, or does it harm? At the end, the reader will have to answer these questions for himself. A framework is offered for guidance through the maze of dimensions that need to be taken into consideration.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Rose K, Della Pasqua O (2011) Development of paediatric medicines: concepts and principles. Handb Exp Pharmacol 205:111–124
Rodriguez W, Maldonado S (2010) United States paediatric legislation impact on paediatric drug studies. In: Rose K, van den Anker JN (eds) Guide to paediatric drug development & clinical research. Karger, Basel
Nakamura H, Ozaki M (2010) Facilitation of paediatric research in Japan. In: Rose K, van den Anker JN (eds) Guide to paediatric drug development & clinical research. Karger, Basel
Ramet J, Lehman B, Rose K (2010) Europe and the path to better medicines for children. In: Rose K, van den Anker JN (eds) Guide to paediatric drug development & clinical research. Karger, Basel
Wright EA, Rose K (2010) European Union paediatric regulation theory and practice. In: Rose K, van den Anker JN (eds) Guide to paediatric drug development & clinical research. Karger, Basel
Boklan J (2006) Little patients, losing patience: pediatric cancer drug. Mol Cancer Ther 5:1905–1908, http://mct.aacrjournals.org/content/5/8/1905.full.pdf
Magrath I, Steliarova-Foucher E, Epelman S et al (2013) Improving cancer care for children and young people 2—paediatric cancer in low-income and middle-income countries. Lancet Oncol 14(3):e104–e116, http://press.thelancet.com/childhoodcancer2.pdf
Pritchard-Jones K, Pieters R, Reaman GH et al (2013) Improving cancer care for children and young people 1—sustaining innovation and improvement in the treatment of childhood cancer: lessons from high-income countries. Lancet Oncol 14(3):e95–e103, http://press.thelancet.com/childhoodcancer1.pdf
Sullivan R, Kowalczyk JR, Agarwal B et al (2013) Improving cancer care for children and young people 4—new policies to address the global burden of childhood cancers. Lancet Oncol 14(3):e125–e135, http://press.thelancet.com/childhoodcancer4.pdf
Vassal G, Zwaan CM, Ashley D (2013) Improving cancer care for children and young people 3—new drugs for children and adolescents with cancer: the need for novel development pathways. Lancet Oncol 14(3):e117–e124, http://press.thelancet.com/childhoodcancer3.pdf
EMA 2012-1 (2012) 5-Year report to the European commission. General report on the experience acquired as a result of the application of the paediatric regulation. 8 July, EMA/428172/2012. http://ec.europa.eu/health/files/paediatrics/2012-09_pediatric_report-annex1-2_en.pdf
Olski TM, Lampus SF, Gherarducci G, Saint-Raymond A (2011) Three years of paediatric regulation in the European union. Eur J Clin Pharmacol 67:245–252
Drews J (2000) Drug discovery: a historical perspective. Science 287:1960–1964
Tassiari M (2012) Pediatric regulations: permanent laws and new provisions under FDASIA. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM332078.pdf
EMA 2012-2 (2012) Medicines agency (EMA): policy on the determination of the condition(s) for a paediatric investigation plan/waiver (scope of the PIP/waiver). http://www.ema.europa.eu/docs/en_GB/document_library/Other/2012/09/WC500133065.pdf
Tomasi P (2012) Writing applications for paediatric investigation plans and waivers. Med Writ 21(2):1–4
Thorat C et al (2012) What the orphan drug act has done lately for children with rare diseases: a 10-year analysis. Pediatrics 129:516–521, http://pediatrics.aappublications.org/content/129/3/516.long
Bodenheimer T (2000) Uneasy alliance. Clinical investigators and the pharmaceutical industry. NEJM 342(20):1539–1544
DiMasi JA, Hansen RW, Grabowski HG (2003) The price of innovation: new estimates of drug development costs. J Health Econ 22:151–185
Rose K (2008) Ethical, regulatory and scientific challenges in paediatric drug development. Pharm Med 22(4):221–234
Adamson P (2013) Developing drugs for pediatric malignancies. Clinical Advances in Hematology & Oncology 11(4):227–229
FDA (2001) The pediatric exclusivity provision - January 2001. Status Report to Congress. http://www.fda.gov/downloads/drugs/developmentapprovalprocess/developmentresources/ucm049915.pdf. Accessed 17 Dec 2013
Rose K (2012) A paediatric investigation plan case study. Pharm Med 26(5):287–295
Heinemann L (2008) Are all clinical studies sponsored by industry not valid? J Diabetes Sci Technol 2(6):1161–1163
Brezis M (2008) Big pharma and health care: unsolvable conflict of interests between private enterprise and public health. Isr J Psychiatry Relat Sci 45(2):83–94
Hilts PJ (2003) Protecting America’s Heath. In Alfred A. Knopf, New York, ISBN 0-375-40466-X
EMA PIP deicision EMEA-000335-PIP01-08-M08 of 30 October 2013. http://www.ema.europa.eu/docs/en_GB/document_library/PIP_decision/WC500154705.pdf. Accessed 16 Dec 2013
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 American Association of Pharmaceutical Scientists
About this chapter
Cite this chapter
Rose, K. (2014). Pediatric Pharmaceutical Legislation in the USA and EU and Their Impact on Adult and Pediatric Drug Development. In: Bar-Shalom, D., Rose, K. (eds) Pediatric Formulations. AAPS Advances in the Pharmaceutical Sciences Series, vol 11. Springer, New York, NY. https://doi.org/10.1007/978-1-4899-8011-3_28
Download citation
DOI: https://doi.org/10.1007/978-1-4899-8011-3_28
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4899-8010-6
Online ISBN: 978-1-4899-8011-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)